tradingkey.logo

OraSure Technologies Inc

OSUR
2.410USD
+0.020+0.84%
收盤 12/22, 16:00美東報價延遲15分鐘
174.16M總市值
虧損本益比TTM

OraSure Technologies Inc

2.410
+0.020+0.84%

關於 OraSure Technologies Inc 公司

OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.

OraSure Technologies Inc簡介

公司代碼OSUR
公司名稱OraSure Technologies Inc
上市日期Nov 17, 1986
CEOEglinton Manner (Carrie)
員工數量501
證券類型Ordinary Share
年結日Nov 17
公司地址220 E First St
城市BETHLEHEM
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編18015
電話15036416115
網址https://www.orasure.com/
公司代碼OSUR
上市日期Nov 17, 1986
CEOEglinton Manner (Carrie)

OraSure Technologies Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-2.72%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
160.25K
+1.33%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
153.32K
+4.16%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+93.09%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+109.45%
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Robert W. Mcmahon
Mr. Robert W. Mcmahon
Independent Director
Independent Director
--
--
Mr. Jason Plagman
Mr. Jason Plagman
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Steven K. (Steve) Boyd
Mr. Steven K. (Steve) Boyd
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-2.72%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
160.25K
+1.33%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
153.32K
+4.16%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+93.09%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+109.45%
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Net product and services revenues - COVID-19
14.40M
46.09%
Net product and services revenues - HIV
9.86M
31.54%
Net product and service revenues -Molecular Products
4.13M
13.21%
Other revenues - Other non Product revenues
1.40M
4.47%
Net product and services revenues - Risk assessment testing
994.00K
3.18%
其他
474.00K
1.52%
地區USD
名稱
營收
佔比
United States
19.85M
63.54%
Africa (Region)
8.03M
25.69%
Europe
2.12M
6.78%
Other Regions
1.25M
3.99%
業務
地區
業務USD
名稱
營收
佔比
Net product and services revenues - COVID-19
14.40M
46.09%
Net product and services revenues - HIV
9.86M
31.54%
Net product and service revenues -Molecular Products
4.13M
13.21%
Other revenues - Other non Product revenues
1.40M
4.47%
Net product and services revenues - Risk assessment testing
994.00K
3.18%
其他
474.00K
1.52%

股東統計

更新時間: 11月15日 週六
更新時間: 11月15日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
7.81%
Private Management Group, Inc.
7.55%
Neuberger Berman, LLC
5.86%
The Vanguard Group, Inc.
5.76%
Altai Capital Management, L.P.
5.21%
其他
67.80%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
7.81%
Private Management Group, Inc.
7.55%
Neuberger Berman, LLC
5.86%
The Vanguard Group, Inc.
5.76%
Altai Capital Management, L.P.
5.21%
其他
67.80%
股東類型
持股股東
佔比
Investment Advisor
36.59%
Investment Advisor/Hedge Fund
27.60%
Hedge Fund
23.49%
Individual Investor
6.13%
Research Firm
2.26%
Pension Fund
0.47%
Bank and Trust
0.29%
Venture Capital
0.11%
Insurance Company
0.04%
其他
3.02%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
451
66.91M
93.28%
-15.50M
2025Q2
473
72.08M
98.55%
-16.70M
2025Q1
483
70.23M
93.78%
-12.52M
2024Q4
475
70.81M
94.94%
-10.37M
2024Q3
471
70.30M
94.28%
-10.80M
2024Q2
477
73.05M
98.74%
-8.54M
2024Q1
473
74.45M
97.36%
-5.59M
2023Q4
464
73.29M
99.74%
-5.62M
2023Q3
456
72.50M
98.73%
-4.51M
2023Q2
452
70.73M
96.51%
-2.77M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
5.43M
7.43%
-141.00K
-2.53%
Jun 30, 2025
Private Management Group, Inc.
5.46M
7.47%
+1.04M
+23.64%
Jun 30, 2025
Neuberger Berman, LLC
4.16M
5.68%
-124.14K
-2.90%
Jun 30, 2025
The Vanguard Group, Inc.
4.17M
5.7%
-120.08K
-2.80%
Jun 30, 2025
Altai Capital Management, L.P.
3.75M
5.13%
+1.59M
+73.37%
Sep 02, 2025
Dimensional Fund Advisors, L.P.
3.84M
5.25%
+14.96K
+0.39%
Jun 30, 2025
Systematic Financial Management, L.P.
2.23M
3.05%
+581.93K
+35.33%
Jun 30, 2025
Renaissance Technologies LLC
2.28M
3.11%
-294.84K
-11.47%
Jun 30, 2025
Acadian Asset Management LLC
2.19M
3%
-563.24K
-20.44%
Jun 30, 2025
Millennium Management LLC
1.23M
1.69%
+28.80K
+2.39%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.44%
iShares US Small Cap Value Factor ETF
0.12%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.05%
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Avantis US Small Cap Equity ETF
0.02%
WisdomTree US SmallCap Fund
0.02%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
DFA Dimensional US Small Cap Value ETF
0.01%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.44%
iShares US Small Cap Value Factor ETF
佔比0.12%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
佔比0.05%
iShares Micro-Cap ETF
佔比0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.04%
Avantis US Small Cap Equity ETF
佔比0.02%
WisdomTree US SmallCap Fund
佔比0.02%
ProShares UltraPro Russell2000
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
DFA Dimensional US Small Cap Value ETF
佔比0.01%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

OraSure Technologies Inc的前五大股東是誰?

OraSure Technologies Inc的前五大股東如下:
BlackRock Institutional Trust Company, N.A.
持有股份:5.43M
佔總股份比例:7.43%。
Private Management Group, Inc.
持有股份:5.46M
佔總股份比例:7.47%。
Neuberger Berman, LLC
持有股份:4.16M
佔總股份比例:5.68%。
The Vanguard Group, Inc.
持有股份:4.17M
佔總股份比例:5.70%。
Altai Capital Management, L.P.
持有股份:3.75M
佔總股份比例:5.13%。

OraSure Technologies Inc的前三大股東類型是什麼?

OraSure Technologies Inc 的前三大股東類型分別是:
BlackRock Institutional Trust Company, N.A.
Private Management Group, Inc.
Neuberger Berman, LLC

有多少機構持有OraSure Technologies Inc(OSUR)的股份?

截至2025Q3,共有451家機構持有OraSure Technologies Inc的股份,合計持有的股份價值約為66.91M,占公司總股份的93.28% 。與2025Q2相比,機構持股有所增加,增幅為-5.27%。

哪個業務部門對OraSure Technologies Inc的收入貢獻最大?

在FY2025Q2,Net product and services revenues - COVID-19業務部門對OraSure Technologies Inc的收入貢獻最大,創收14.40M,占總收入的46.09% 。
KeyAI